Skip to main content
Narinder Bhalla, MD, Cardiology, Wilmington, DE

NarinderPBhallaMD

Cardiology Wilmington, DE

Interventional Cardiology

SVP, Worldwide Medical Affairs Head of Cardiovascular and Established Brands Bristol Myers Squibb Lawrenceville, New Jersey, USA

Dr. Bhalla is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Bhalla's full profile

Already have an account?

  • Office

    1800 Concord Pike
    Wilmington, DE 19803
    Phone+1 302-886-3000

Education & Training

  • Icahn School of Medicine at Mount Sinai/Mount Sinai Hospital
    Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalFellowship, Interventional Cardiology, 1995 - 1996
  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineFellowship, Cardiovascular Disease, 1992 - 1995
  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineResidency, Internal Medicine, 1988 - 1992
  • Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo
    Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1988

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1990 - 2025
  • VA State Medical License
    VA State Medical License 1999 - 2018
  • AL State Medical License
    AL State Medical License 2008 - 2017

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2013
  • Fellow (FACC) American College of Cardiology

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Retrospective Observational Study Assessing Real-World Clinical Impact of Switching or Continuing Eliquis® or Rivaroxaban Presented at the European Society of Cardiology (ESC) Congress 2023
    Retrospective Observational Study Assessing Real-World Clinical Impact of Switching or Continuing Eliquis® or Rivaroxaban Presented at the European Society of Cardiology (ESC) Congress 2023August 26th, 2023

Professional Memberships